# Connect Biopharma (CNTB) — Analyst Forecast

CNTB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cntb/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 8 | 0 | 0 | 8 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $4.00 | $5.40 | $7.00 | 5 |

Last price $0.91 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 12, 2026 | Leerink Partners | Initiated Coverage | Outperform | $4.00 |
| Oct 8, 2026 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Oct 2, 2026 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Sep 30, 2026 | BTIG | Maintained | Buy | $5.00 |
| Sep 22, 2026 | Oppenheimer | Maintained | Outperform | $5.00 |
| Sep 17, 2026 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Sep 16, 2026 | Canaccord Genuity | Maintained | Buy | $6.00 |
| Sep 15, 2026 | BTIG | Maintained | Buy | $10.00 |
| Jul 9, 2026 | Oppenheimer | Initiated Coverage | Outperform | $8.00 |
| Jun 26, 2026 | Piper Sandler | Initiated Coverage | Neutral → Overweight | $7.00 |
| Jun 25, 2026 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| May 26, 2026 | Canaccord Genuity | Initiated Coverage | Buy | $6.00 |
| May 21, 2026 | Cantor Fitzgerald | Initiated Coverage | Overweight | $4.00 |
| Apr 1, 2026 | BTIG | Maintained | Buy | $10.00 |
| Mar 31, 2026 | BTIG | Maintained | Buy | $10.00 |
| Dec 1, 2025 | Lake Street | Initiated Coverage | Buy | $9.00 |
| Nov 13, 2025 | BTIG | Maintained | Buy | $10.00 |
| Oct 31, 2025 | BTIG | Initiated Coverage | Buy | $10.00 |
| Aug 13, 2025 | HC Wainwright & Co. | Maintained | Buy | $7.00 |
| Jun 12, 2025 | HC Wainwright & Co. | Initiated Coverage | Buy | $7.00 |

## Frequently Asked Questions

### What is the price target for CNTB stock?

The average 12-month analyst price target for Connect Biopharma (CNTB) is $5.40, with a high estimate of $7.00 and a low of $4.00, across 5 analysts.

### Is CNTB a buy, sell, or hold?

Analysts covering Connect Biopharma currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for CNTB?

The average price target of $5.40 implies 495.89% upside from the last price of $0.91.

### What is the latest analyst rating on CNTB?

On Oct 12, 2026, Leerink Partners initiated coverage of Connect Biopharma at Outperform with a price target of $4.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).